The complement system as a therapeutic target
The complement system has a key role in the innate immune system, and its dysregulation is involved in a wide range of diseases. Building on the success of pioneering drugs that specifically target the complement system to treat several rare diseases, there is growing interest in pursuing novel targets in the system and expanding the range of diseases in which complement-targeted drugs could be applied. This collection brings together a poster and a selection of recent reviews describing the role of the complement system in various diseases and the opportunities for therapeutic intervention.
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the discovery, development and commercialization of life-changing medicines. Our innovation begins with understanding people living with rare diseases, which fuels all of our efforts, beginning with our own medicine discovery efforts, as well as collaboration with external partners. This allows us to innovate and evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives. For more information about Alexion, please visit www.Alexion.com.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. For more than 20 years, Roche has been pioneering haematology science and has achieved approvals for multiple medicines spanning both malignant hematology and rare blood disorders. Roche is currently investigating complement inhibition in paroxysmal nocturnal haemoglobinuria.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society.
For more information, please visit www.roche.com.
Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our latest treatments. About 105 000 people of more than 140 nationalities work at Novartis around the world. Find out more at www.novartis.com.
